Small Lymphocytic Lymphoma

Fixed-duration first-line treatment with ibrutinib plus venetoclax induced deep, durable responses among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, according to results of the phase 2 CAPTIVATE study.

Zanubrutinib induced a superior overall response rate compared with ibrutinib among patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, according to study results.

The addition of copanlisib to rituximab extended PFS among patients with relapsed indolent non-Hodgkin lymphoma who received prior rituximab-containing therapy, according to topline data released by the agent’s manufacturer.

The FDA approved ibrutinib in combination with rituximab for treatment of newly diagnosed patients chronic lymphocytic leukemia or small lymphocytic lymphoma.